Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Co-Diagnostics Inc (CODX)

Co-Diagnostics Inc (CODX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 341,489
  • Shares Outstanding, K 28,269
  • Annual Sales, $ 210 K
  • Annual Income, $ -6,200 K
  • 60-Month Beta -3.30
  • Price/Sales 6.32
  • Price/Cash Flow N/A
  • Price/Book 6.35
Trade CODX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.49
  • Number of Estimates 1
  • High Estimate 0.49
  • Low Estimate 0.49
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +590.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.01 +38.51%
on 12/29/20
12.69 -1.65%
on 01/26/21
+1.64 (+15.13%)
since 12/24/20
3-Month
9.01 +38.51%
on 12/29/20
16.96 -26.42%
on 11/13/20
-1.56 (-11.11%)
since 10/26/20
52-Week
2.06 +504.42%
on 01/29/20
30.99 -59.73%
on 08/03/20
+10.60 (+563.83%)
since 01/24/20

Most Recent Stories

More News
Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis

, /PRNewswire/ -- As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however,...

LXG.VN : 1.050 (+0.96%)
LXXGF : 0.8312 (+1.16%)
CODX : 12.48 (+3.31%)
MMM : 175.95 (+3.26%)
MIR.VN : 0.355 (+5.97%)
MMIRF : 0.2632 (+1.23%)
ABT : 114.73 (+0.01%)
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

, /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...

CODX : 12.48 (+3.31%)
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

, /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...

CODX : 12.48 (+3.31%)
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

, /PRNewswire/ -- Co-Diagnostics, Inc. (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...

CODX : 12.48 (+3.31%)
Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold

, /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...

CODX : 12.48 (+3.31%)
A New Surge in Cases Emphasizes the Need for Effective Diagnostics

, /PRNewswire/ -- As of earlier this week, the U.S. has reported more than 13.6 million cases and over 269,348 deaths, according to . Dr. of the National Institute of Allergy and Infectious Diseases,...

OPK : 5.26 (+4.78%)
TOMDF : 0.0572 (-4.67%)
CODX : 12.48 (+3.31%)
NVAX : 127.16 (-3.27%)
PFE : 37.31 (+0.08%)
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

, /PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...

CODX : 12.48 (+3.31%)
Maxim Group & H.C. Wainwright Analysts Confirm Co-Diagnostics (NADSAQ:CODX) Buy Rating with PTs of $20 and $29

The global upsurge in COVID-19 has kept testing and Co-Diagnostics (NASDAQ: CODX) under the analysts' microscope.

CODX : 12.48 (+3.31%)
The Need for Precise Testing Capabilities is Clear as Cases Surge

, /PRNewswire/ -- Recent reports from across the country clearly show that infection cases are once again surging. More than 11.4 million Americans have now been infected with the virus and the number...

OPK : 5.26 (+4.78%)
TOMDF : 0.0572 (-4.67%)
CEMI : 6.84 (+4.43%)
CODX : 12.48 (+3.31%)
VIR : 77.38 (+74.32%)
Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests

, /PRNewswire/ -- Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC...

CODX : 12.48 (+3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology...

See More

Key Turning Points

3rd Resistance Point 13.43
2nd Resistance Point 13.06
1st Resistance Point 12.77
Last Price 12.48
1st Support Level 12.11
2nd Support Level 11.74
3rd Support Level 11.45

See More

52-Week High 30.99
Fibonacci 61.8% 19.94
Fibonacci 50% 16.53
Fibonacci 38.2% 13.11
Last Price 12.48
52-Week Low 2.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar